China's Livzon to acquire 65 per cent of pharmaceutical firm Imexpharm

May 27, 2025 | 11:19

(0) user say

China's Livzon Pharmaceutical Group Inc. will spend VND5.73 trillion ($221 million) to acquire just under 65 per cent of Imexpharm Corporation from its major shareholders.

China's Livzon to acquire 65 per cent of pharmaceutical firm Imexpharm

Livzon announced the deal to acquire a 64.81 per cent stake in Imexpharm, on May 22, marking one of the largest merger and acquisition deals in Vietnam's pharmaceutical industry in recent time.

The deal is being conducted by Lian SGP Holding Pte. Ltd., a company incorporated in Singapore, and is an indirect wholly owned subsidiary of Livzon.

According to the agreement, Livzon has agreed to purchase the shares from SK Investment Vina III Pte. Ltd under SK Group, Sunrise Kim Investment JSC, and KBA Investment JSC.

The purchase price was set through arm’s length negotiations, based on Imexpharm’s market value, reflected by its 30-day average market capitalisation of approximately $269 million, as of May 21 on the Ho Chi Minh Stock Exchange.

The transaction value is equivalent to an average price of VND57,300 ($2.21) apiece. After the transaction, Livzon becomes the largest shareholder holding a controlling stake in Imexpharm. Imexpharm will become a subsidiary and be incorporated into the financial statements of the Chinese pharmaceutical company.

The acquisition will lay a solid foundation for Livzon's further expansion into overseas markets, supporting its long-term strategy of internationalisation and sustainable development in the pharmaceutical sector.

Quality can shine through in Japanese M&A developments

Japanese dealmakers are eager to step up dealmaking activity across all sectors in Vietnam. Masataka “Sam” Yoshida, head of the Cross-border Division at RECOF Corporation, discussed with VIR’s Thanh Van the performance and prospects of Japanese mergers and acquisitions in Vietnam.